EPS for Endologix, Inc. (ELGX) Expected At $-0.22; Baldwin & Lyons (BWINB)’s Sentiment Is 1.31

February 15, 2018 - By Vivian Park

Analysts expect Endologix, Inc. (NASDAQ:ELGX) to report $-0.22 EPS on February, 28.They anticipate $0.00 EPS change or 0.00% from last quarter’s $-0.22 EPS. After having $-0.11 EPS previously, Endologix, Inc.’s analysts see 100.00% EPS growth. The stock decreased 6.19% or $0.25 during the last trading session, reaching $3.79. About 4.06 million shares traded or 553.95% up from the average. Endologix, Inc. (NASDAQ:ELGX) has declined 63.00% since February 15, 2017 and is downtrending. It has underperformed by 79.70% the S&P500.

Baldwin & Lyons, Inc., together with its subsidiaries, engages in marketing and underwriting property and casualty insurance products primarily in the United States. The company has market cap of $339.21 million. The firm operates through two divisions, Property and Casualty Insurance, and Reinsurance. It has a 51.37 P/E ratio. It provides a range of fleet transportation insurance products, such as commercial motor vehicle liability, physical damage, and other liability insurance; workers compensation insurance; specialized accident that include medical and indemnity insurance products for independent contractors; non-trucking motor vehicle liability insurance for independent contractors; fidelity and surety bonds; and inland marine products consisting of cargo insurance.

Investors sentiment increased to 1.07 in 2017 Q3. Its up 0.25, from 0.82 in 2017Q2. It increased, as 21 investors sold Endologix, Inc. shares while 22 reduced holdings. 17 funds opened positions while 29 raised stakes. 83.13 million shares or 3.94% less from 86.54 million shares in 2017Q2 were reported. Manufacturers Life The stated it has 0% in Endologix, Inc. (NASDAQ:ELGX). Partner Fund Management Ltd Partnership holds 0.58% in Endologix, Inc. (NASDAQ:ELGX) or 6.66M shares. Ubs Asset Mgmt Americas accumulated 34,898 shares. Rhumbline Advisers invested in 0% or 96,866 shares. Aperio Grp Inc Limited Liability invested 0% of its portfolio in Endologix, Inc. (NASDAQ:ELGX). Axa reported 0.02% stake. Citadel Advsr Ltd holds 0% or 87,809 shares in its portfolio. 24,333 are held by Legal & General Group Plc. State Street Corporation invested in 1.77M shares. Credit Suisse Ag holds 84,964 shares or 0% of its portfolio. Mpm Asset Limited Liability Corp, a Massachusetts-based fund reported 1.12 million shares. Royal Bank & Trust Of Canada reported 0% of its portfolio in Endologix, Inc. (NASDAQ:ELGX). 29,935 were accumulated by Stoneridge Inv Prns Lc. Brown Cap Management Limited Com has invested 0.48% in Endologix, Inc. (NASDAQ:ELGX). Great West Life Assurance Com Can holds 0% of its portfolio in Endologix, Inc. (NASDAQ:ELGX) for 6,683 shares.

Among 10 analysts covering Endologix Inc. (NASDAQ:ELGX), 3 have Buy rating, 1 Sell and 6 Hold. Therefore 30% are positive. Endologix Inc. had 44 analyst reports since August 4, 2015 according to SRatingsIntel. The stock has “Hold” rating by Canaccord Genuity on Monday, September 25. As per Tuesday, November 3, the company rating was maintained by Piper Jaffray. The firm has “Underweight” rating by JP Morgan given on Tuesday, January 2. The stock has “Hold” rating by Stifel Nicolaus on Thursday, May 18. BMO Capital Markets maintained Endologix, Inc. (NASDAQ:ELGX) on Wednesday, October 11 with “Hold” rating. As per Tuesday, August 4, the company rating was downgraded by Canaccord Genuity. On Friday, September 8 the stock rating was maintained by BMO Capital Markets with “Hold”. The stock has “Mkt Perform” rating by Leerink Swann on Tuesday, September 6. Stifel Nicolaus maintained the stock with “Hold” rating in Friday, October 6 report. The rating was maintained by Canaccord Genuity on Monday, July 10 with “Hold”.

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company has market cap of $316.29 million. It offers minimally-invasive endovascular repair products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system. It currently has negative earnings. The firm also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens.

The stock decreased 0.66% or $0.15 during the last trading session, reaching $22.55. About 15,027 shares traded. Baldwin & Lyons, Inc. (BWINB) has declined 3.36% since February 15, 2017 and is downtrending. It has underperformed by 20.06% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts